Research Article

The Role of IFN-γ Level In The Patients of Non-Small Cell Carcinoma And Small Cell Carcinoma of Lung Cancer At IV Stage Compared With Other Stages

Abstract

IFN- γ used as a marker to know the suppression or development of disease of lung cancer, 200 samples were collected from lung cancer disease patients, where all cases of the disease were collected from the center of Middle Euphrates Cancer in AL-Najaf City (January 2023 to April 2023), with 130 and 70 samples for both males and females and 80 samples represented the control group and were divided into 50 and 30 samples for males and females respectively, the age, smoking and types of lung cancer factors such as sex, age, and subtypes of main types of lung cancer disease that were taken in studying research. All samples which 155 cases were comprised of non-small cell carcinoma cases of patients representing 78% divided into 75 (38%) cases of squamous cell carcinoma, 50 (25%) cases of adenocarcinoma (33.3%), and 30 (15%) cases of large cell carcinoma, while 45 (22%) represented cases of small cell carcinoma, the blood samples from all patients cases have separated the serum form plasma to detect levels of IFN- γ by (ELISA) apparatus to measure its levels of IFN- γ in the patients’ serum of lung cancer, the results were (0.3995±0.00282) pg/ml increased significantly at (p ≤ 0.05) compared with the control group (0.2009±0.003593) pg/ml, the study also was showed significantly (p ≤ 0.05) at stage IV of the disease (0.1971±0.04218) pg/ml in comparison with stage III (0.184±0.05346) pg/ml and stage I-II (0.1708±0.08292) pg/ml. Furthermore, the study observed IFN- γ levels in the patients’ serum of a type of lung cancer for NSCLC (0.4632±0.05331) pg/ml increased significantly (p ≤ 0.05) compared with type SCLC (0.2003±0.06652) pg/ml in addition to high significant in subtypes adenocarcinoma (0.5984±0.05379) pg/ml compared with squamous cell carcinoma (0.4973±0.04301) pg/ml and large cell carcinoma (0.294±0.06313) pg/ml.